Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Epilepsy: Vigabatrin treatment and visual field loss.

Literature DB >> 21364521

Epilepsy: Vigabatrin treatment and visual field loss.

Catherine Chiron, Olivier Dulac.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2011 PMID： 21364521 DOI： 10.1038/nrneurol.2011.25

Source DB: PubMed Journal: Nat Rev Neurol ISSN： 1759-4758 Impact factor: 42.937

× No keyword cloud information.

10 in total

Review 1. Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review.

Authors: Melissa J Maguire; Karla Hemming; John M Wild; Jane L Hutton; Anthony G Marson
Journal: Epilepsia Date: 2010-11-10 Impact factor: 5.864

2. Severe relapse of epilepsy after vigabatrin withdrawal: for how long should we treat symptomatic infantile spasms?

Authors: Judith Kröll-Seger; Anna Kaminska; Marie Laure Moutard; Anne de Saint-Martin; Agnes Guët; Olivier Dulac; Catherine Chiron
Journal: Epilepsia Date: 2007-03 Impact factor: 5.864

3. Mental and behavioural outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients.

Authors: I Jambaqué; C Chiron; C Dumas; J Mumford; O Dulac
Journal: Epilepsy Res Date: 2000-02 Impact factor: 3.045

4. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis.

Authors: C Chiron; C Dumas; I Jambaqué; J Mumford; O Dulac
Journal: Epilepsy Res Date: 1997-01 Impact factor: 3.045

5. Infantile spasms in Down syndrome: good response to a short course of vigabatrin.

Authors: R Nabbout; I Melki; B Gerbaka; O Dulac; C Akatcherian
Journal: Epilepsia Date: 2001-12 Impact factor: 5.864

6. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial.

Authors: Andrew L Lux; Stuart W Edwards; Eleanor Hancock; Anthony L Johnson; Colin R Kennedy; Richard W Newton; Finbar J K O'Callaghan; Christopher M Verity; John P Osborne
Journal: Lancet Neurol Date: 2005-11 Impact factor: 44.182

1 in total

1. Therapeutic efficacy of magnesium valproate in succinic semialdehyde dehydrogenase deficiency.

Authors: Elena Vanadia; K Michael Gibson; Phillip L Pearl; Emanuele Trapolino; Salvatore Mangano; Francesca Vanadia
Journal: JIMD Rep Date: 2012-08-22

1 in total

Epilepsy: Vigabatrin treatment and visual field loss.

Review 1. Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review.

2. Severe relapse of epilepsy after vigabatrin withdrawal: for how long should we treat symptomatic infantile spasms?

3. Mental and behavioural outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients.

4. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis.

5. Infantile spasms in Down syndrome: good response to a short course of vigabatrin.

6. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial.

7. Visual fields at school-age in children treated with vigabatrin in infancy.

8. In utero exposure to vigabatrin: no indication of visual field loss.

9. Changes in the electroretinogram resulting from discontinuation of vigabatrin in children.

10. Nasal retinal nerve fiber layer attenuation: a biomarker for vigabatrin toxicity.

1. Therapeutic efficacy of magnesium valproate in succinic semialdehyde dehydrogenase deficiency.